SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Big Dog's Boom Boom Room
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TheBusDriver who wrote (79424)2/4/2007 9:58:50 AM
From: rolatzi  Read Replies (2) of 206118
 
Re: Biotech
I have been in Celgene (CELG) for the last 6 or 7 years and I think it has another two to three years to run. The company's drug Revlimid, after a most successful launch this past year, will receive approval in European Community in the next three months which will probably double the current market, and will see increased use for additional blood cancer indications over the next year or two. Another drug, CC-1004 is in mid-development phase (first indication for psoriasis) and will probably see positive research reports at the professional meetings in June (ASCO) and December (ASH) with approval likely sometime in late 2008 or 2009.

A more speculative play is Dendreon (DNDN) which is being considered for approval with a prostate cancer vaccine (Provenge). The decision date is May of this year. The results of the human study may not be robust enough for approval, but the use is for terminal patients initially. There is probably a 75% chance for approval. However, the stock is heavily shorted, manipulated and is under priced. If not approved, it is likely to receive approvable letter which would require an additional human trial. Management is acting like they believe approval is assured but you never know.

Ciao,
rolatzi
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News